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Abstract
Hyaluronan (HA), which is a major component of the extracellular matrix (ECM), is regulated during myofibropro-
liferative responses to numerous forms of inflammatory stimuli. It is a key factor involved in cellular migration and
adherence. The development of a potent and non-toxic inhibitor of HA synthesis would open up a new avenue for the
treatment of fibrocontractive diseases such as pulmonary fibrosis and liver cirrhosis. In this study, the effects of vesnarinone
(OPC-8212: 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone) on the secretion of HA in human
myofibroblast cell lines (MRC-5 and LI90 cells, referred to as pulmonary and hepatic myofibroblasts, respectively) were
examined. Vesnarinone specifically and dose-dependently inhibited HA secretion by myofibroblasts up-regulated by fetal calf
serum (FCS). The treatment of vesnarinone did not modify the phenotype of myofibroblast cells in culture. Vesnarinone also
potently inhibited the HA secretion by the two myofibroblast cell lines up-regulated by transforming growth factor-L1 (TGF-
L1) or tumor necrosis factor-K (TNF-K). The addition of vesnarinone to myofibroblasts resulted in a significant decrease of
HA synthase (HAS) activity, with or without the addition of FCS or either cytokine. These findings suggest that vesnarinone
inhibits the secretion of HA in myofibroblasts by specifically suppressing HAS activity, and may therefore prove useful for
the treatment of chronic inflammation and tissue fibrosis. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
It has been suggested that hyaluronan (HA) plays
a key role in several biological processes, including
embryonic development [1], wound healing [2,3], and
tumor growth and metastasis [4,5], by providing a
provisional matrix for supporting cellular migration
and adhesion [6,7]. HA, a linear glycosaminoglycan
consisting of D-glucuronic acid (1-L-3) N-acetyl-D-
glucosamine (1-L-4) disaccharide repeats, is a major
component of extracellular matrix (ECM) that
undergoes dynamic regulation during in£ammation
[8]. HA is synthesized at the cell surface by the mem-
brane-bound enzyme HA synthase (HAS) [9]. In par-
ticular, the hallmarks of chronic in£ammation and
tissue ¢brosis are increased synthesis and degrada-
tion of ECM components. The dynamic turnover
of ECM results in the net deposition of matrix in
the interstitium of the a¡ected tissue. Mohamadza-
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deh et al. recently reported that HA expression on
cultured endothelial cells can be up-regulated by
proin£ammatory cytokines such as tumor necrosis
factor-K (TNF-K) and interleukin-1K (IL-1K) [10].
We also reported that TNF-K can enhance HA syn-
thesis via the transcriptional induction of HAS on
cultured myo¢broblasts [11]. HA-speci¢c binding
proteins (receptors) have been identi¢ed on many
di¡erent cells, e.g. the lymphocyte homing receptor
CD44 [10]. Thus, the proin£ammatory cytokines
such as TNF-K can induce the binding between
HA and CD44, facilitating endothelial cell- or myo-
¢broblast-leukocyte interactions at sites of in£amma-
tion.
The molecular mechanism that regulates the bio-
synthesis of HA has not yet been clari¢ed, but a
number of stimulatory factors, in addition to the
proin£ammatory cytokines TNF-K and IL-1, have
been identi¢ed [8]. For example, several growth fac-
tors such as epidermal growth factor, platelet-derived
growth factor (PDGF) and transforming growth
factor-L (TGF-L) stimulate the synthesis of HA
[12]. Of the many cytokines that have been impli-
cated in wound healing, TGF-L a¡ects all phases of
the healing process, including the in£ammatory re-
sponse and ECM accumulation [13]. Meanwhile, var-
ious tumor cell-produced growth factors, including
TGF-L, have been reported to stimulate HA synthe-
sis by ¢broblasts and are therefore believed to con-
tribute to the expression of an invasive phenotype
[14,15].
The quinolinone derivative vesnarinone (OPC-
8212), with the chemical formula 3,4-dihydro-6-[4-
(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinoli-
none, is an orally active inotropic agent with a rela-
tively broad spectrum of pharmacological actions
and has been widely used for the treatment of pa-
tients with heart failure [16]. The inotropic activity of
vesnarinone was found to be associated with a de-
crease in potassium currents, the inhibition of phos-
phodiesterase type III activity and an increase in in-
ward calcium currents, suggesting that one or more
of these e¡ects is involved in the inotropic action of
vesnarinone [16]. Subsequent to these observations,
vesnarinone was reported to inhibit the invasive ac-
tivity of some tumor cell lines, both in vitro and in
vivo [17,18]. The mechanism of the anti-invasive ac-
tion is not yet understood.
In the present study, we investigated whether ves-
narinone inhibits the secretion of HA by cultured
myo¢broblasts with or without the addition of
stimulatory substances such as fetal calf serum
(FCS), TGF-L1 and TNF-K and whether the inhibi-
tory e¡ects of this agent are dependent on the mod-
ulation of HA biosynthesis via changes in HAS ac-
tivity.
2. Materials and methods
2.1. Reagents
UDP-GlcUA was purchased from Nakarai Tesque
(Kyoto, Japan). UDP-GlcNAc was purchased from
Sigma Chemical (St. Louis, MO, USA). UDP-
[14C]GlcUA (320.2 mCi/mmol) was purchased from
DuPont NEN (Boston, MA, USA). Streptomyces
hyaluronidase was purchased from Seikagaku (To-
kyo, Japan). A Hiload 16/60 Superdex 30 pg column
was purchased from Pharmacia Biotech (Tokyo, Ja-
pan). Recombinant human TGF-L1 and vesnarinone
were obtained from Otsuka Pharmaceutical (Tokyo,
Japan). TNF-K was purchased from Amgen Biolog-
icals (Thousand Oaks, CA, USA). The stock solution
of vesnarinone (2 mg/ml) was prepared by dissolving
the drug in 1 N HCl, followed by neutralization with
1 N NaOH. The stock solution was prepared imme-
diately before use, ¢ltered and diluted with complete
medium.
2.2. Cell culture
A human embryonic lung-derived ¢broblast cell
line, MRC-5 (CCL-171), was obtained from the
American Type Culture Collection (Rockville, MD,
USA). MRC-5 cells were grown in Dulbecco’s modi-
¢ed Eagle’s medium (DMEM, Nissui, Tokyo, Japan)
supplemented with 10% FCS (Gibco Laboratories,
Grand Island, NY, USA) at 37‡C under 5% CO2/
95% air. The cells were subcultured every 4 days.
LI90 cells, which exhibit characteristics compatible
with those of human activated Ito cells, were also
cultured as previously described [19]. For prolifera-
tion assays, myo¢broblast cells were cultured in
6-well plates (Costar, Cambridge, MA, USA) at
4U104 cells/well in 10% FCS for 96 h.
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2.3. Measurement of HA secretion
MRC-5 cells were seeded at 2U104 cells per well in
a 24-well plate (Becton Dickson Labware, Oxnard,
CA, USA) in DMEM containing 10% FCS. The me-
dium, supplemented with 0.5% or 10% FCS, was
changed after 48 h. Vesnarinone was simultaneously
added at various concentrations (15, 30 or 60 Wg/ml).
These concentrations were selected because the blood
concentrations of this agent are generally in the
range of 10^30 Wg/ml in clinical application [12]. At
4 days, the culture medium was collected for the
measurement of HA secretion. In order to study
the e¡ects of some stimulatory factors on cultured
myo¢broblasts, the two cell lines (MRC-5 and LI90
cells) were cultured to con£uence in DMEM supple-
mented with 10% FCS. The cells were then washed
twice and incubated in fresh medium with TNF-K
(250 U/ml) or TGF-L1 (5 ng/ml) for 48 h. Each fac-
tor was presented at e¡ective concentrations, as pre-
viously described [11,19]. Vesnarinone at 60 Wg/ml
(the maximally e¡ective concentration in vitro) was
added at the same time as the factors [17]. The con-
ditioned medium was collected and clari¢ed by cen-
trifugation at 12 000Ug for 5 min. HA was measured
by a sandwich enzyme-binding assay [20]. The level
of laminin was determined with the use of enzyme
immunoassay kits [19]. The concentration of collagen
IV was determined with the RIA kit (Nippon DPC
Corporation, Tokyo, Japan) using a polyclonal anti-
body to 7S collagen as reported [21]. The cells were
washed twice with phosphate-bu¡ered saline and
treated with 0.125% trypsin. After the cells were
stained with 0.2% trypan blue, the number of cells
was calculated with a hemocytometer.
2.4. RNA extraction and ampli¢cation using reverse
transcription-polymerase chain reaction
(RT-PCR)
Total RNA from the harvest cells was isolated by
the acid guanidium-thiocyanate-phenol-chloroform
method [11] and 2 Wg of total RNA was converted
to cDNA by reverse transcriptase (Superscript, Gib-
co). The ampli¢cation procedure consisted of 30
cycles (94‡C, 40 s; 60‡C, 30 s; 72‡C, 1.5 min) with
the following oligonucleotide primer sets [11,22]. The
K-smooth muscle actin (K-SMA) forward primer was
5P-CCA GCT ATG TGA AGA AGA GG-3P ; the
reverse was 5P-GTG ATC TCC TTC TGC ATT
CGG T-3P (the pair generated a 965 bp fragment).
The human TGF-L1 forward primer sequence was
5P-GCC CTG GAC ACC AAC TAT TGC-3P ; the
reverse was 5P-GCT GCA CTT GCA GGA GCG
CAC-3P (the pair generated a 336 bp fragment).
The primer set of glyceraldehyde-3-phosphate dehy-
drogenase (G3PDH) was purchased from Toyobo
(Osaka, Japan; the pair generated a 452 bp frag-
ment). Each ¢nal PCR product was electrophoresed
on a 1% agarose gel.
2.5. HAS assay
MRC-5 cells (1.8U106 cells) were seeded in a 15
cm tissue culture dish (Becton Dickson Labware) and
incubated in DMEM with 10% FCS for 72 h. They
were washed twice and cultured in fresh medium
with TNF-K (250 U/ml) or TGF-L1 (5 ng/ml) for
48 h. Vesnarinone (0, 15, 30 or 60 Wg/ml) was added
at the same time as the factors. The cells were sus-
pended in 0.25 M sucrose containing 10 mM HEPES
and 0.5 mM dithiothreitol (pH 7.2) and cooled in an
ice bath during three cycles of disruption for 5 s
each. Large pieces of debris in the suspension were
removed by centrifugation at 600Ug for 10 min. The
supernatant was collected and centrifuged at
105 000Ug for 1 h. The resultant ‘crude membrane’
pellet was suspended in 0.2 ml of 25 mM HEPES^
NaOH (pH 7.1), 5 mM dithiothreitol, 15 mM
MgCl2, 1 mM UDP-GlcNAc, 0.05 mM UDP-GlcUA
and 2.5 WCi of UDP-[14C]GlcUA as described previ-
ously [23]. The protein content was determined using
a protein assay kit (Bio-Rad, Hercules, CA, USA).
After the reaction at 37‡C for 1 h, the mixture was
further incubated with or without one turbidity re-
ducing unit of Streptomyces hyaluronidase at 37‡C
for 1 h and then boiled in the presence of 1% sodium
dodecyl sulfate. [14C]HA was separated by chroma-
tography on a Superdex H 16/60 column and eluted
with 0.2 M ammonium acetate. The radioactivity in-
corporated into HA was calculated as Streptomyces
hyaluronidase-sensitive radioactivity [11].
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3. Results
3.1. E¡ect of vesnarinone on the secretion of HA in
the presence of FCS in MRC-5 cells
Since PDGF puri¢ed from human platelets has
been shown to stimulate HA synthesis in cultured
¢broblasts [12], we investigated the e¡ect of vesnar-
inone treatment on the secretion of HA in MRC-5
cells maintained in DMEM containing 0.5% or 10%
FCS. As expected, the secretion rate of HA on a per
cell basis in MRC-5 cells in the absence of vesnar-
inone was signi¢cantly increased in DMEM contain-
ing the higher concentration of FCS compared with
the lower concentration (Fig. 1). The addition of
vesnarinone to MRC-5 cells in DMEM containing
10% FCS resulted in a dose-dependent inhibition of
the HA secretion (Fig. 1). On MRC-5 cells incubated
in DMEM containing the lower concentration of
FCS (0.5%), the inhibition of HA secretion induced
by the treatment with vesnarinone (60 Wg/ml) was
comparable to that achieved in culture with 10%
FCS (Fig. 1).
We investigated the e¡ect of vesnarinone on the
expression of K-SMA mRNA in cultured myo¢bro-
blasts. As shown in Fig. 2, MRC-5 cells expressed
the mRNA of K-SMA, in addition to that of TGF-
L1, but the treatment of these cells with vesnarinone
(at maximally e¡ective concentration) resulted in no
changes in the levels of both mRNA species. There-
fore, the addition of vesnarinone neither modi¢ed
myo¢broblasts phenotype nor a¡ected the expression
of TGF-L1, which can induce myo¢broblast pheno-
type.
3.2. E¡ect of vesnarinone on the secretion of HA in
human myo¢broblasts cultured with stimulatory
factors
The speci¢c population of myo¢broblasts appears
to play an important role in the tissue ¢brosis asso-
ciated by prolonged in£ammation such as pulmonary
¢brosis and liver cirrhosis [24]. We recently reported
the biochemical features of MRC-5 cells, referred to
as pulmonary myo¢broblasts [11]. We have also
shown that the functional characteristics of LI90
Fig. 2. RT-PCR analysis of mRNAs of K-SMA, TGF-L1 and
G3PDH in MRC-5 cells treated with vesnarinone. PCR-ampli-
¢ed products from cDNAs generated in reverse transcriptase re-
action from 2 mg of total RNA from MRC-5 cells using sense
and antisense primers speci¢c for K-SMA, TGF-L1 and
G3PDH. The predicted size of the K-SMA product is 965 bp,
that of the TGF-L1 product is 336 bp and that of the G3PDH
product is 452 bp. The mRNA levels of K-SMA and TGF-L1
were identical in both the absence (lanes 1, 4 and 7) and pres-
ence (lanes 2, 5 and 8) of vesnarinone. Molecular weight
markers from V/HindIII-digested PX174 are indicated (lanes 3,
6 and 9). Analyses were repeated at least twice, and all tested
samples showed similar results.
Fig. 1. Reduction in HA secretion by vesnarinone in MRC-5
cells treated with 0.5 or 10% FCS. MRC-5 cells were cultured
in 24-well plates in DMEM containing 10% FCS. After 48 h,
the medium supplemented with 0.5% or 10% FCS was changed,
and vesnarinone was added at the indicated concentrations. The
amount of HA in the culture medium was normalized per 104
cells. The results shown are means for three experiments, and
the error bars indicate S.E.M.
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cells are compatible with those of human activated
Ito cells, which are known as hepatic myo¢broblasts
[19]. The e¡ects of vesnarinone on the secretion of
HA in these cultured myo¢broblast cell lines stimu-
lated by TGF-L1 and TNF-K were examined. The
results of the HA-binding assay are shown in Fig.
3. Vesnarinone did not a¡ect the growth of either
myo¢broblast cell line at the highest concentration
tested (Fig. 3). The TGF-L1 treatment produced a
signi¢cant increase in HA secretion by both cell lines,
whereas TNF-K was found to have a stimulatory
e¡ect on the secretion rate of HA in MRC-5 cells,
but not LI90 cells.
The addition of vesnarinone to the two cell lines in
the presence of each stimulatory factor resulted in a
signi¢cant decrease in HA secretion (Fig. 3). Unlike
the inhibitory e¡ect of vesnarinone on HA secretion
by cultured myo¢broblasts, the production of some
other components of ECM, such as laminin or col-
lagen type IV, was not a¡ected (Fig. 4). The growth
inhibitory response of several cancer cell lines to ves-
narinone both in vitro and in vivo has been reported
[17,18]. These results suggest that vesnarinone specif-
ically suppresses the secretion of HA both with and
without the addition of stimulatory factors. Since the
decrease in detectable HA in the cultured medium of
myo¢broblasts treated with vesnarinone could be due
to changes in HA biosynthesis and/or degradation, it
is essential to evaluate the changes in HAS activity in
treated myo¢broblasts.
3.3. E¡ect of vesnarinone on HAS activity
In recent studies, no signi¢cant changes in the lev-
els of HAS mRNA were detected in cultured endo-
thelial cells treated with TNF-K for 4 h [10]. How-
ever, we more recently showed detectable changes in
the activity of HAS to explain the signi¢cant in-
creases observed in HA production with the addition
of TNF-K for 48 h to MRC-5 cells. It should be
noted that there are multiple vertebrate HAS genes
Fig. 4. E¡ect of vesnarinone on the secretion of laminin and
collagen IV in MRC-5 cells. MRC-5 cells were cultured to con-
£uence in DMEM supplemented with 10% FCS. The cells were
washed twice and incubated in fresh medium in the absence or
presence of vesnarinone (60 Wg/ml; at maximally e¡ective con-
centration). The amount of laminin and collagen IV in the cul-
ture medium after 48 h was normalized per 104 cells. The re-
sults shown are means for three experiments, and the error bars
indicate S.E.M.
Fig. 3. E¡ect of vesnarinone on the growth (upper) and secre-
tion of HA (lower) in human myo¢broblasts treated with TNF-
K and TGF-L1. Human myo¢broblasts (MRC-5 and LI90 cells)
were incubated in the presence of TNF-K (250 U/ml) and TGF-
L1 (5 ng/ml). Vesnarinone (60 Wg/ml) was added at the same
time as the factors. The cell numbers were counted after 96 h.
The amount of HA in the culture medium for 48 h was nor-
malized per 104 cells. The results shown are means for three ex-
periments, and the error bars indicate S.E.M.
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encoding di¡erent HAS subtypes (HAS-1, -2 and -3)
[9]. In order to evaluate the regulation of HA biosyn-
thesis, it is important to determine the net activity of
HAS in stimulated cells. Thus, we examined the ef-
fect of vesnarinone on the activity of HAS in MRC-5
cells treated in the presence and absence of stimula-
tory factors (Fig. 5). Under the untreated condition,
the addition of vesnarinone at a concentration of 60
Wg/ml resulted in a signi¢cant decrease in HAS activ-
ity to 52% of the control level (Fig. 5). The HAS
activity on MRC-5 cells was enhanced by TGF-L1
and by TNF-K, and vesnarinone potently and dose-
dependently inhibited the activity of this enzyme in
treated cells (Fig. 5). Therefore, it appears that
changes in the activity levels of HAS, which is the
central enzyme in the HA biosynthetic pathway, are
responsible for the decreased HA secretion observed
in cultured myo¢broblasts treated with vesnarinone.
4. Discussion
In this study, we obtained the ¢rst evidence that a
quinolinone derivative, vesnarinone, can potently in-
hibit HA biosynthesis via HAS activity in human
myo¢broblasts. HA function is mediated by interac-
tions with speci¢c binding proteins on the cell sur-
face. CD44, a known cell surface HA-binding pro-
tein, is normally present on leukocytes in an inactive
state that cannot bind HA [25]. Of particular interest
is a more recent study by Maiti et al. which demon-
strated that TNF-K converted CD44 from its inac-
tive, non-binding form to its active form by inducing
the sulfation of CD44 [26]. We have also reported
that TNF-K can increase HA synthesis by its stimu-
latory e¡ect on HAS activity mediated by the p50/
p65 NF-kB complex on cultured myo¢broblasts [11].
Thus, proin£ammatory cytokines such as TNF-K
may regulate initial adhesion by optimizing the bind-
ing of HA to CD44 to facilitate the rolling and ex-
travasation of leukocytes at sites of in£ammation.
The term ‘myo¢broblasts’ was ¢rst used by Majno
et al. to de¢ne spindle cells of connective tissue that
exhibit ultrastructural features of both smooth
muscle cells and ¢broblasts [27]. Myo¢broblasts dis-
appear from normal scars, but persist in ¢brotic le-
sions of many tissues, where they are involved in
ECM accumulation as well as in retractile phenom-
ena [24]. In our recent studies, the marked increase
observed in HA synthesis in two human cultured cell
lines (MRC-5 and LI90 cell), which exhibit the bio-
chemical features of myo¢broblasts, treated with
TNF-K and TGF-L1 suggests that HA plays a role
in a prolonged in£ammation predisposing to ¢bro-
contractive diseases [11,19]. Interestingly, McBride
and Bard demonstrated that the HA-rich matrices
(halos) protect cells from cytotoxic lymphocytes
[28]. The organization of HA-halos around myo¢-
broblasts can help them to escape attack by cytotoxic
cells, resulting in ECM accumulation by a large num-
ber of remaining cells at the ¢brotic sites. These ¢nd-
ings suggest that inhibitors of HAS might be thera-
peutically useful for inhibiting the production of HA,
thereby reducing the accumulation of ECM in tissue
¢brosis associated with in£ammation. Indeed, the
administration of vesnarinone signi¢cantly sup-
pressed the development of hepatic ¢brosis in CCl4-
treated rats in vivo1.
Since vesnarinone can potently inhibit the net ac-
Fig. 5. Inhibition of HAS activity by vesnarinone in MRC-5
cells treated with TNF-K and TGF-L1. MRC-5 cells were cul-
tured to con£uence in DMEM supplemented with 10% FCS,
washed twice and incubated in fresh medium with TNF-K (250
U/ml) and TGF-L1 (5 ng/ml). Vesnarinone at the indicated con-
centrations was added at the same time as the factors. The
crude membrane proteins were prepared and the speci¢c activity
of HAS was assayed as described in Section 2. The results
shown are means for three experiments, and the error bars indi-
cate S.E.M.
1 Personal communication from Dr. Masahisa Kyogoku (Sci-
enti¢c Advisor Otsuka Pharmaceutical, Professor Emeritus Toho-
ku University).
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tivity of HAS in myo¢broblasts treated with various
stimulatory substances, we can rule out the possibil-
ity that this agent in£uences the intrinsic receptor
expression or signaling process of each agonistic fac-
tor. Although the HAS protein is required for HA
synthesis, the eukaryotic HAS protein is larger than
that of bacteria [9]. Therefore, their additional pro-
tein domains could be involved in more elaborate
functions such as intracellular tra⁄cking and local-
ization, the regulation of enzyme activity, and medi-
ating interactions with other cellular components.
Sequence analysis of human HAS-1 recently revealed
several sites that are phosphorylated by protein ty-
rosine kinase, protein kinase C and casein kinase II
[29]. Conceivably, the unique pharmacological ac-
tions of vesnarinone on the HA synthesis in myo¢-
broblasts could be due to an antagonistic e¡ect on
the catalytic domain of the HA-synthesizing activity
or to a modulatory e¡ect on additional domains of
HAS, thus inhibiting its translocation to plasma
membrane or its interactions with other regulatory
proteins such as some protein kinases. Interestingly,
Yoshinaka et al. suggested that vesnarinone may in-
directly activate the tyrosine phosphorylation of
membrane proteins related to cell adhesion [30]. Fur-
ther investigations are necessary to address the com-
plicated issue of vesnarinone as an exploitable target
for one or more of the cellular components that reg-
ulate the human HAS activity.
In the adult, a transient elevation in the concen-
tration of HA in granulation tissue coincides with
periods of the in£ux of in£ammatory cells during
wound healing, while a persistent increase in the
HA concentration characterizes the stroma associ-
ated with malignant tumors [31,32]. The organization
of HA-halos surrounding stromal cells such as my-
o¢broblasts may play a role in both tumor cell at-
tachment and migration during tumor invasion and
may be involved in the expression of an invasive
phenotype. The increases in HA synthesis observed
in some carcinoma cells have been shown to be re-
lated to a high potential of metastasis [4]. If HA
synthesis by cancer cells or myo¢broblasts in tumor
stroma could be suppressed by the application of
synthetic inhibitors, it might be possible to reduce
tumor invasiveness and metastasis. A recent study
obtained evidence that vesnarinone can inhibit the
invasiveness of several tumor cells [17]. Therefore,
vesnarinone, as a potent inhibitor of HA synthesis,
may be a useful agent for the treatment of malignant
tumors with an invasive phenotype and may also be
of use in the development of new strategies for can-
cer treatment.
In summary, the results of the present study sug-
gest that vesnarinone may prove to be useful not
only as an inhibitory agent for myo¢broproliferative
diseases accompanied by in£ammation, but also as a
tool in pharmacological studies on the mechanisms
and regulation of HA synthesis via HAS in vitro.
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